Cargando…

Next-generation PET/CT imaging in meningioma—first clinical experiences using the novel SSTR-targeting peptide [(18)F]SiTATE

BACKGROUND: Somatostatin-receptor (SSTR)-targeted PET/CT provides important clinical information in addition to standard imaging in meningioma patients. [(18)F]SiTATE is a novel, (18)F-labeled SSTR-targeting peptide with superior imaging properties according to preliminary data. We provide the first...

Descripción completa

Detalles Bibliográficos
Autores principales:	Unterrainer, Marcus, Kunte, Sophie C., Unterrainer, Lena M., Holzgreve, Adrien, Delker, Astrid, Lindner, Simon, Beyer, Leonie, Brendel, Matthias, Kunz, Wolfgang G., Winkelmann, Michael, Cyran, Clemens C., Ricke, Jens, Jurkschat, Klaus, Wängler, Carmen, Wängler, Björn, Schirrmacher, Ralf, Belka, Claus, Niyazi, Maximilian, Tonn, Joerg-Christian, Bartenstein, Peter, Albert, Nathalie L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10541820/ https://www.ncbi.nlm.nih.gov/pubmed/37358620 http://dx.doi.org/10.1007/s00259-023-06315-z

Ejemplares similares

Correction to: Next‑generation PET/CT imaging in meningioma—first clinical experiences using the novel SSTR‑targeting peptide [(18)F]SiTATE
por: Unterrainer, Marcus, et al.
Publicado: (2023)

Favorable SSTR subtype selectivity of SiTATE: new momentum for clinical [(18)F]SiTATE PET
por: Wängler, Carmen, et al.
Publicado: (2022)

Dosimetry and optimal scan time of [(18)F]SiTATE-PET/CT in patients with neuroendocrine tumours
por: Beyer, Leonie, et al.
Publicado: (2021)

Comparison of somatostatin receptor expression in patients with neuroendocrine tumours with and without somatostatin analogue treatment imaged with [(18)F]SiTATE
por: Eschbach, Ralf S., et al.
Publicado: (2023)

Detection of Splenic Tissue Using (99m)Tc-Labelled Denatured Red Blood Cells Scintigraphy—A Quantitative Single Center Analysis
por: Holzgreve, Adrien, et al.
Publicado: (2022)

Good practices for the automated production of (18)F-SiFA radiopharmaceuticals
por: Blok, Simon, et al.
Publicado: (2023)

Validation of the SSTR-RADS 1.0 for the structured interpretation of SSTR-PET/CT and treatment planning in neuroendocrine tumor (NET) patients
por: Grawe, Freba, et al.
Publicado: (2023)

(68)Ga-EMP-100 PET/CT—a novel method for non-invasive assessment of c-MET expression in non-small cell lung cancer
por: Unterrainer, Lena M., et al.
Publicado: (2022)

(18)F-Labeled Silicon-Based Fluoride Acceptors: Potential Opportunities for Novel Positron Emitting Radiopharmaceuticals
por: Bernard-Gauthier, Vadim, et al.
Publicado: (2014)

PSMA-Expression Is Highly Associated with Histological Subtypes of Renal Cell Carcinoma: Potential Implications for Theranostic Approaches
por: Bui, Vinh Ngoc, et al.
Publicado: (2023)

Total Tumor Volume on (18)F-PSMA-1007 PET as Additional Imaging Biomarker in mCRPC Patients Undergoing PSMA-Targeted Alpha Therapy with (225)Ac-PSMA-I&T
por: Unterrainer, Lena M., et al.
Publicado: (2022)

Metabolic patterns on [(18)F]FDG PET/CT in patients with unresectable stage III NSCLC undergoing chemoradiotherapy ± durvalumab maintenance treatment
por: Holzgreve, Adrien, et al.
Publicado: (2023)

Recent Advances in the Clinical Translation of Silicon Fluoride Acceptor (SiFA) (18)F-Radiopharmaceuticals
por: Gower-Fry, Lexi, et al.
Publicado: (2021)

t-Bu(2)SiF-Derivatized D(2)-Receptor Ligands: The First SiFA-Containing Small Molecule Radiotracers for Target-Specific PET-Imaging
por: Iovkova-Berends, Ljuba, et al.
Publicado: (2011)

Can Radiomics Provide Additional Information in [(18)F]FET-Negative Gliomas?
por: von Rohr, Katharina, et al.
Publicado: (2022)

(18)F-FET PET Uptake Characteristics of Long-Term IDH-Wildtype Diffuse Glioma Survivors
por: Mittlmeier, Lena M., et al.
Publicado: (2021)

Increased TSPO PET signal after radiochemotherapy in IDH-wildtype glioma—indicator for treatment-induced immune activation?
por: Quach, Stefanie, et al.
Publicado: (2022)

(18)F-FDG PET/CT for Response Assessment in Pediatric Sebaceous Carcinoma of the Parotid Gland
por: Holzgreve, Adrien, et al.
Publicado: (2020)

In response to: Anatomy of (18)F-GE180, a failed radioligand for the TSPO protein
por: Albert, Nathalie L., et al.
Publicado: (2020)

TERT-Promoter Mutational Status in Glioblastoma – Is There an Association With Amino Acid Uptake on Dynamic (18)F-FET PET?
por: Unterrainer, Marcus, et al.
Publicado: (2021)

Longitudinal [(18)F]GE-180 PET Imaging Facilitates In Vivo Monitoring of TSPO Expression in the GL261 Glioblastoma Mouse Model
por: Holzgreve, Adrien, et al.
Publicado: (2022)

Combination of pre-treatment dynamic [(18)F]FET PET radiomics and conventional clinical parameters for the survival stratification in patients with IDH-wildtype glioblastoma
por: Li, Zhicong, et al.
Publicado: (2022)

PET/CT imaging for tumour response assessment to immunotherapy: current status and future directions
por: Unterrainer, Marcus, et al.
Publicado: (2020)

Feasibility of [(68)Ga]Ga-FAPI-46 PET/CT for detection of nodal and hematogenous spread in high-grade urothelial carcinoma
por: Unterrainer, Lena M., et al.
Publicado: (2022)

Postoperative [(68)Ga]Ga-DOTA-TATE PET/CT imaging is prognostic for progression-free survival in meningioma WHO grade 1
por: Teske, Nico, et al.
Publicado: (2023)

In response to: PSMA PET/CT cost-effectiveness analysis in the USA: a response to a published commentary
por: Holzgreve, Adrien, et al.
Publicado: (2023)

Bimodal Imaging Probes for Combined PET and OI: Recent Developments and Future Directions for Hybrid Agent Development
por: Seibold, Uwe, et al.
Publicado: (2014)

Identification of a Suitable Peptidic Molecular Platform for the Development of NPY(Y(1))R‐Specific Imaging Agents
por: Krieger, Korbinian, et al.
Publicado: (2020)

Clinical Significance of Somatostatin Receptor (SSTR) 2 in Meningioma
por: Wu, Wei, et al.
Publicado: (2020)

Prognostic Value of TSPO PET Before Radiotherapy in Newly Diagnosed IDH–Wild-Type Glioblastoma
por: Albert, Nathalie L., et al.
Publicado: (2023)

Immature Plasma Cell Myeloma Mimics Metastatic Renal Cell Carcinoma on (18)F-PSMA-1007 PET/CT Due to Endothelial PSMA-Expression
por: Mittlmeier, Lena M., et al.
Publicado: (2021)

Sarcoid-Like Reaction in Non-Hodgkin’s Lymphoma—A Diagnostic Challenge for Deauville Scoring on (18)F-FDG PET/CT Imaging
por: Winkelmann, Michael, et al.
Publicado: (2021)

(89)Zr, a Radiometal Nuclide with High Potential for Molecular Imaging with PET: Chemistry, Applications and Remaining Challenges
por: Fischer, Gabriel, et al.
Publicado: (2013)

iEDDA Conjugation Reaction in Radiometal Labeling of Peptides with (68)Ga and (64)Cu: Unexpected Findings
por: Litau, Shanna, et al.
Publicado: (2018)

Towards Radiolabeled EGFR-Specific Peptides: Alternatives to GE11
por: Judmann, Benedikt, et al.
Publicado: (2023)

Synthesis of a Bifunctional Cross‐Bridged Chelating Agent, Peptide Conjugation, and Comparison of (68)Ga Labeling and Complex Stability Characteristics with Established Chelators
por: Damerow, Helen, et al.
Publicado: (2022)

Is PSMA PET/CT cost-effective for the primary staging in prostate cancer? First results for European countries and the USA based on the proPSMA trial
por: Holzgreve, Adrien, et al.
Publicado: (2023)

(18)F-PSMA-1007 PET/CT for response assessment in patients with metastatic renal cell carcinoma undergoing tyrosine kinase or checkpoint inhibitor therapy: preliminary results
por: Mittlmeier, L. M., et al.
Publicado: (2020)

Differential role of residual metabolic tumor volume in inoperable stage III NSCLC after chemoradiotherapy ± immune checkpoint inhibition
por: Unterrainer, Marcus, et al.
Publicado: (2021)

Differences in the expression of SSTR1–5 in meningiomas and its therapeutic potential
por: Behling, Felix, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_trq42ucsh5bp6606q7mfg4102q